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OBJECTIVE—Glucagon-like peptide-1 (GLP-1) and gastrin pro-
mote pancreatic -cell function, survival, and growth. Here, we
investigated whether GLP-1 and gastrin can restore the -cell
mass and reverse hyperglycemia in NOD mice with autoimmune
diabetes.
RESEARCH DESIGN AND METHODS—Acutely diabetic
NOD mice were treated with GLP-1 and gastrin, separately or
together, twice daily for 3 weeks. Blood glucose was measured
weekly and for a further 5 weeks after treatments, after which
pancreatic insulin content and -cell mass, proliferation, neogen-
esis, and apoptosis were measured. Insulin autoantibodies were
measured, and adoptive transfer of diabetes and syngeneic islet
transplant studies were done to evaluate the effects of GLP-1 and
gastrin treatment on autoimmunity.
RESULTS—Combination therapy with GLP-1 and gastrin, but
not with GLP-1 or gastrin alone, restored normoglycemia in
diabetic NOD mice. The GLP-1 and gastrin combination in-
creased pancreatic insulin content, -cell mass, and insulin-
positive cells in pancreatic ducts, and -cell apoptosis was
decreased. Insulin autoantibodies were reduced in GLP-1– and
gastrin-treated NOD mice, and splenocytes from these mice
delayed adoptive transfer of diabetes in NOD-scid mice. Synge-
neic islet grafts in GLP-1– and gastrin-treated NOD mice were
inﬁltrated by leukocytes with a shift in cytokine expression from
interferon- to transforming growth factor-1, and -cells were
protected from apoptosis.
CONCLUSIONS—Combination therapy with GLP-1 and gastrin
restores normoglycemia in diabetic NOD mice by increasing the
pancreatic -cell mass and downregulating the autoimmune
response. Diabetes 57:3281–3288, 2008
P
ancreatic -cells can regenerate in response to
experimental injury in adult animals (1–3) and
can increase in humans in response to conditions
such as pregnancy (4) and obesity (5). In addi-
tion, there is histological evidence of attempts at -cell
regeneration in humans with type 1 diabetes (6,7). Simi-
larly, -cell proliferation is increased before diabetes
onset in NOD mice, an animal model for human type 1
diabetes, but not sufﬁciently to keep up with the ongoing
autoimmune response that decreases the -cell mass (8).
Therefore, therapies directed at stimulating -cell regen-
eration in addition to arresting autoimmunity may restore
the -cell mass and reverse type 1 diabetes.
Many putative -cell growth factors have been identi-
ﬁed, one of the most promising being glucagon-like pep-
tide-1 (GLP-1), a peptide secreted from intestinal L-cells in
response to nutrient ingestion (9). The actions of GLP-1 to
stimulate glucose-dependent insulin secretion and inhibit
glucagon release, gastric emptying, and food intake (10)
have led to its application as a therapy for type 2 diabetes
(11). GLP-1 has additional actions that suggest a thera-
peutic role in conditions with a deﬁcit in -cell mass.
GLP-1 and long-acting GLP-1 receptor agonists, such as
exendin-4, increase the -cell mass in rodents with surgi-
cally or chemically induced diabetes through stimulation
of -cell proliferation and islet neogenesis and inhibition
of -cell apoptosis (12–15). Also, GLP-1 (16) and exendin-4
(17) reduce insulitis and protect -cells in NOD mice when
given before diabetes onset. Exendin-4 has also been
reported to reverse diabetes in NOD mice; however, this
required combination of exendin-4 with immunosuppres-
sive therapy using antilymphocyte serum (18).
Gastrin is a gastrointestinal peptide reported to induce
-cell neogenesis from pancreatic exocrine duct cells in
rodents (19,20). Combined gastrin and epidermal growth
factor (EGF) treatment induces islet regeneration and
restores normoglycemia in alloxan-treated mice (21) and
ameliorates hyperglycemia after diabetes onset in NOD
mice (22). Here, we report that addition of gastrin to GLP-1
treatment restored normoglycemia in acutely diabetic
NOD mice by increasing the pancreatic -cell mass and
downregulating the autoimmune response.
RESEARCH DESIGN AND METHODS
NOD female mice, 6–8 weeks of age, were purchased from Taconic (German-
town, NY). NOD-scid female mice were purchased from The Jackson Labora-
tories (Bar Harbor, ME). The mice were housed and fed under speciﬁc
pathogen-free conditions and were cared for according to the guidelines of the
Canadian Council on Animal Care. The NOD mice were monitored daily by
urine testing using Keto-Diastix reagent strips (Bayer, Etobicoke, ON, Can-
ada). Diabetes onset was diagnosed by the presence of glucosuria (6
mmol/l), ketonuria (1.5 mmol/l), and a nonfasting blood glucose 10 mmol/l
measured at 4:00–6:00 P.M. on 2 consecutive days using a blood glucose meter
and test strip (Ascencia Elite; Bayer). Treatments were started within 3–6
days after diabetes onset in 12- to 16-week-old NOD mice.
Diabetes treatments. Acutely diabetic NOD mice of similar ages were
randomly allocated into seven groups: a pretreatment (baseline) group and six
groups treated for 3 weeks with twice-daily intraperitoneal injections of PBS
vehicle (control), 10 g/kg GLP-1, 100 g/kg GLP-1, 1.5 g/kg gastrin, 10 g/kg
GLP-1 plus 1.5 g/kg gastrin, and 100 g/kg GLP-1 plus 1.5 g/kg gastrin.
GLP-1 was synthetic human GLP-1 [7-36] amide (Bachem, Torrance, CA).
Gastrin was human gastrin-17 synthesized and puriﬁed to 97% by high-
performance liquid chromatography (Starr Biochemicals, Torrance, CA). This
gastrin-17 has a leucine substitution for methionine at position 15 to prevent
oxidation and is equipotent to native gastrin-17 (23). GLP-1 and gastrin
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mmol/l NaPO4 (pH 7.4) at a stock concentration of 3 g/ml, stored in aliquots
at 70°C, then thawed, diluted in sterile PBS (pH 7.4), kept at 4°C, and used
within 2 days. No insulin treatments were given. Blood glucose concentrations
were measured in nonfasted mice at 4:00–6:00 P.M. once a week for 3 weeks
during treatments and for another 5 weeks after treatments were stopped.
Mice with blood glucose levels 27.5 mmol/l and losing weight were killed by
sodium pentobarbital overdose before 8 weeks; all other mice were killed at
8 weeks (study end). Blood was collected for C-peptide and insulin autoanti-
body assays. Pancreata were removed, kept on ice, cleaned of fat and lymph
nodes, weighed, and divided longitudinally from head to tail into two equal
portions to assay insulin content and for histological studies.
Plasma C-peptide. C-peptide levels in plasma were measured using a
radioimmunoassay kit speciﬁc for rat or mouse C-peptide (Linco Research, St.
Charles, MO).
Insulin autoantibodies. Insulin autoantibodies in serum were measured by
a method previously described (24).
Pancreatic insulin content. One-half of each pancreas was weighed, minced
with ﬁne scissors in 1.0 ml acidiﬁed ethanol (75% ethanol, 1.5% 12 mmol/l HCl,
and 23.5% H2O), and incubated for 24 h at 4°C to extract insulin from tissue.
The ethanolic extracts were diluted in assay buffer, and insulin was measured
using a radioimmunoassay kit for mouse insulin (Linco).
Pancreatic histology. The other half of each pancreas was ﬁxed in 10%
buffered formalin and embedded in parafﬁn. Serial sections 4.5 m thick were
cut. Deparafﬁnized sections were stained for -cells by an immunoperoxidase
technique. The sections were incubated with a guinea pig anti-insulin antibody
(Dako, Carpenteria, CA), and then with a biotinylated goat anti–guinea pig
antibody (Vector, Burlingame, CA) and a streptavidin peroxidase conjugate
and chromogen (iso-IHC 3,3-diaminobenzidine (DAB) kit; InnoGenex, San
Ramon, CA). Sections were counterstained with hematoxylin.
Pancreatic -cell mass. -Cell mass was determined by point-counting
morphometry on the insulin-immunostained pancreatic sections using a Nikon
E400 microscope connected to a video camera with a color monitor at
magniﬁcation 265. Each section was counted using a 192-point grid; at least
100 ﬁelds were counted for each tissue block. The -cell relative volume was
calculated by dividing the number of points over insulin-positive cells by the
number of points over the total pancreatic tissue. -Cell mass was determined
by multiplying the -cell relative volume by the total weight of the pancreas.
Pancreatic -cell replication, apoptosis, and neogenesis. Pancreatic
sections were ﬁrst treated with a blocking reagent for mouse antigens
(Ventana Medical Systems, Tucson, AZ). Replicating -cells were identiﬁed by
staining for insulin as described for the pancreatic histology studies and then
by incubation with a mouse anti-human monoclonal antibody (mAb) (clone
PC-10; Dako) to the proliferating cell nuclear antigen (PCNA), followed by a
universal secondary antibody and streptavidin alkaline phosphatase-blue kit
(Ventana). To identify -cells in apoptosis, pancreatic sections immuno-
stained for -cells were then stained using the terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL) method and a cell
death detection kit (Roche Diagnostics, Laval, QC, Canada), followed by a
streptavidin alkaline phosphatase-blue kit (Ventana). Replicating duct cells
were identiﬁed by staining for PCNA
 nuclei, followed by a mouse anti-human
cytokeratin 20 (CK20) mAb (Dako) that identiﬁes rodent ductal epithelial cells
capable of islet cytodifferentiation (25), and then by a biotinylated goat
anti-human antibody and a streptavidin peroxidase–red kit (Ventana). Pancre-
atic duct cells that expressed insulin were identiﬁed by staining for insulin and
then for duct cells using the CK20 mAb, followed by a biotinylated goat
anti-human antibody and a streptavidin alkaline phosphatase-blue kit (Ven-
tana). Sections were counterstained with 0.2% methyl green. Three sections
(each 15–25 mm
2) cut 200 m apart were scanned for each set of stainings for
each pancreas using the Scanscope Imagescope system (Aperio Technologies,
Vista, CA) at magniﬁcation 40. The digital images were analyzed with
Scanscope software (Aperio), and the number of positive signals as a
percentage of the total (positive plus negative) signals representing the total
pancreatic tissue area scanned was determined by the Positive Pixel Count
Algorithm (Aperio).
Adoptive transfer of diabetes. Diabetic NOD mice treated with PBS vehicle
for 3 weeks and with a blood glucose of 20–25 mmol/l provided diabetogenic
splenic cells. Diabetic NOD mice that were treated with 100 g/kg GLP-1 and
1.5 g/kg gastrin for 3 weeks and that became normoglycemic (3.5–6.5
mmol/l) for 5 further weeks without treatments provided splenic cells to be
tested for immunoregulatory activity. Splenic cells were pooled from six
diabetic NOD mice and separately from six NOD mice treated with GLP-1 and
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FIG. 1. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning 3–6 days after diabetes onset (0 weeks) and for
the next 3 weeks, NOD mice were treated with twice-daily intraperitoneal injections of vehicle (n  6), 10 g/kg GLP-1 (n  7), 100 g/kg GLP-1
(n  7), 1.5 g/kg gastrin (n  4), 10 g/kg GLP-1 plus 1.5 g/kg gastrin (n  6), and 100 g/kg GLP-1 plus 1.5 g/kg gastrin (n  7). Blood glucose
concentrations in individual mice are shown during the 3 weeks of treatments and for the additional 5 weeks after treatments were stopped.
†Mice with blood glucose levels >27.5 mmol/l and losing weight were killed. Shaded bars show the normal range for blood glucose (3.5–6.5
mmol/l).
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were injected intravenously into ﬁve to eight NOD-scid mice. Diabetes
development in the NOD-scid mice was determined by daily monitoring for
glucosuria and then by detecting a blood glucose 12 mmol/l.
Islet transplantation. Islets were isolated from 6- to 8-week-old NOD female
mice by collagenase digestion of the pancreas and Ficoll density gradient
centrifugation and then hand-picked. Islet transplant recipients were NOD
female mice that had developed diabetes and been treated with 0.5 unit of a
1:1 mix of regular pork and beef insulin (Eli Lilly, Indianapolis, IN) given by
subcutaneous injection once daily for 3–5 weeks before transplantation. Five
hundred islets, pooled from three to four donor NOD mice, were transplanted
under the left renal capsule in each diabetic NOD mouse 24 h after withdrawal
of insulin, as previously described (26). The islet recipient mice were treated
from the time of islet transplantation (day 0) with either PBS vehicle or 100
g/kg GLP-1 and 1.5 g/kg gastrin, given twice daily by intraperitoneal
injection. Blood glucose returned to normal (3.5–6.5 mmol/l) for the ﬁrst 5
days after islet transplantation in all mice. In the ﬁrst study, the mice were
monitored for recurrence of hyperglycemia (12 mmol/l), and islet grafts
were examined histologically. In the second study, islet grafts were removed
at 10 days after transplantation and examined by immunocytochemistry for
cell composition.
Islet graft histology. Islet grafts were removed with a portion of underlying
kidney, ﬁxed, embedded, sectioned, and stained for -cells using an immuno-
peroxidase technique, as was done for the pancreatic histology studies.
Immunocytochemistry of islet grafts. Islet grafts were cut into small pieces
with ﬁne scissors, disrupted by syringe injection through progressively
narrower gauge needles, and dissociated into single cells by incubation in
Ca
2 Mg
2-free PBS with 0.2 mg/ml EDTA (Life Technologies, Burlington, ON,
Canada). Total -cells and -cells in replication or apoptosis were identiﬁed
by immunocytochemical methods, as previously described (27). Brieﬂy, cells
were ﬁxed in 4% paraformaldehyde and placed on glass glides coated with
3-aminopropyltriethoxysilane. To identify replicating -cells, cells were
stained with a guinea pig anti-insulin antibody, followed by staining with an
antibody to PCNA, as for the pancreatic sections. To identify -cells in
apoptosis, cells were stained with a guinea pig anti-insulin antibody and then
with a biotinylated goat anti–guinea pig antibody and a streptavidin alkaline
phosphatase conjugate and chromogen (5-bromo-4-chloro-3-indolyl phos-
phate/nitroblue tetrazolium kit; Biomeda, Foster City, CA). This was followed
by staining using the TUNEL method and a cell death detection kit (Roche)
and then a streptavidin peroxidase conjugate and a DAB nickel chromogen
(Vector).
Leukocytes from islet grafts were stained with a rat mAb to mouse total
leukocytes (CD45
 cells [Ly-5/T200]) or rat IgG control antibody and then
biotinylated goat anti-rat mouse-absorbed IgG and streptavidin alkaline phos-
phatase conjugate and chromogen kit (Biomeda). Cytokine production by the
CD45
 leukocytes was detected by methods previously described (27).
Brieﬂy, the CD45-stained cell preparations were permeabilized by incubation
in 0.3% saponin in PBS and then stained with either a rat anti-mouse
interferon- (IFN-) mAb (XMG 1.2, rat IgG1; Cedarlane, Hornby, ON, Canada)
or rat IgG1 control antibody. Other slides were stained with either a rabbit
antibody speciﬁc for transforming growth factor-1 (TGF-1) (sc-146; Santa
Cruz Biotechnology, Santa Cruz, CA) or rabbit IgG control antibody. Biotin-
ylated rabbit anti-rat mouse-absorbed IgG was the secondary antibody for the
anti–IFN- primary antibody, and biotinylated goat anti-rabbit IgG was the
secondary antibody for the anti–TGF-1 primary antibody. All slides were
incubated with a streptavidin peroxidase conjugate and DAB nickel chromo-
gen (Vector). Cell preparations were stained in duplicate with each test or
control antibody, and 3,000 cells were scored by two independent observers
who each scanned 60 different microscopic ﬁelds (oil immersion, 100).
Statistical analyses. Data are expressed as means 	 SE. The Mann-Whitney
rank sum test was used to compare two groups, and a one-way ANOVA
followed by Dunnett’s multiple comparison test was used when more than two
groups were compared. Correlations were analyzed by nonlinear regression
and ANOVA. P 
 0.05 was considered signiﬁcant. All analyses were done using
InStat 3 Windows (GraphPad Software, San Diego, CA).
RESULTS
Effects of GLP-1 and gastrin on blood glucose and
body weight. The diabetic mice treated with vehicle for 3
weeks were killed at 3–7 weeks because of weight loss
(from 24.7 	 0.7 to 22.8 	 0.5 g, n  6) and severe
hyperglycemia (27.5 mmol/l) (Fig. 1). Treatment with
GLP-1 for 3 weeks restored normoglycemia (3.5–6.5
mmol/l) at 4–8 weeks in two of seven mice that received
10 g/kg GLP-1 and also in two of seven mice treated with
100 g/kg GLP-1. Treatment with gastrin slowed hypergly-
cemia progression in some mice; however, none of four
mice that received gastrin alone was normoglycemic at 8
weeks. In contrast, 10 g/kg GLP-1 plus gastrin restored
normoglycemia in four of six mice at 4–8 weeks, and 100
g/kg GLP-1 plus gastrin restored normoglycemia in seven
of seven mice at 4–8 weeks (Fig. 1). The GLP-1– and
gastrin-treated mice that became normoglycemic (11 of
13) gained weight, from 25.2 	 0.5 to 27.1 	 0.6 g, as they
aged over 8 weeks, similar to nondiabetic mouse strains.
Pancreatic insulin content. Fig. 2A shows that the
pancreatic insulin content in acutely diabetic mice before
treatments (1.42 	 0.40 g) was greatly reduced after 3
weeks of vehicle treatment (0.04 	 0.02 g). Pancreatic
insulin content was not signiﬁcantly different from the
pretreatment level in mice that received gastrin, 10 g/kg
GLP-1, or 100 g/kg GLP-1. In contrast, combined treat-
ment with 10 g/kg GLP-1 and gastrin increased pancre-
atic insulin content threefold over the pretreatment level
(4.75 	 2.00 vs. 1.42 	 0.40 g; P  0.10, NS), and 100
g/kg GLP-1 plus gastrin increased pancreatic insulin
content ﬁvefold over the pretreatment level (7.61 	 1.97
vs. 1.42 	 0.40 g; P 
 0.01). Pancreatic insulin content in
acutely diabetic mice before treatment (1.42 	 0.40 g)
was 14% of normal (10.25 	 0.85 g), whereas 100 g/kg
GLP-1 plus gastrin increased pancreatic insulin content to
74% of normal (7.61 	 1.97 vs. 10.25 	 0.85 g).
-
I
n
s
u
i
n
 
c
o
n
t
e
n
t
(
u
g
/
p
a
n
c
r
e
a
s
)
NOD after treatment
NOD-scid
NOD before treatment
(6) (6) ) 7 ( ) 4 ( ) 5 ( (4) (6) (7)
GLP-1 ug/kg
Gastrin ug/kg
0
0
100
0
0
1.5
10
1.5
100
1.5
10
0
-
-
-
-
0
2
4
6
8
10
12
β
-
c
e
l
l
 
m
a
s
s
(
m
g
/
p
a
n
c
r
e
a
s
)
β
(6) (6) ) 7 ( ) 4 ( ) 5 ( (4) (6) (7)
GLP-1 ug/kg
Gastrin ug/kg
0
0
100 
0
0
1.5
10
1.5
100
1.5
10
0
-
- -
0.0
0.5
1.0
1.5
2.0
A
B
**
*
FIG. 2. GLP-1 and gastrin combination therapy increases pancreatic
insulin content (A) and -cell mass (B) in NOD mice. Pancreata were
removed from acutely diabetic NOD mice before and after 3 weeks of
the treatments indicated plus an additional 5 weeks after treatments
were stopped or sooner if the mice were killed because of severe
diabetes as shown in Fig. 1. NOD-scid mice provide normal values for
pancreatic insulin content (A) and -cell mass (B). Values are means 
SE. *P < 0.05, **P < 0.01 vs. pretreatment values for the numbers of
mice shown in parentheses.
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DIABETES, VOL. 57, DECEMBER 2008 3283Plasma C-peptide. Plasma C-peptide levels reﬂected pan-
creatic insulin contents. The plasma C-peptide level in the
mice treated with 100 g/kg GLP-1 and gastrin (0.95 	 0.18
pmol/ml, n  6) was 50% of the C-peptide level in
normoglycemic NOD-scid mice (1.96 	 0.13 pmol/ml, n 
6) and barely detectable in vehicle-treated mice (0.03 	
0.01 pmol/ml).
Pancreatic -cell mass. Fig. 2B shows that the pancre-
atic -cell mass in acutely diabetic mice before treatments
(0.25 	 0.10 mg) was greatly reduced in vehicle-treated
mice (0.01 	 0.01 mg). Pancreatic -cell mass was not
signiﬁcantly different from the pretreatment level in mice
that received gastrin, 10 g/kg GLP-1, or 100 g/kg GLP-1.
In contrast, combined treatment with 10 g/kg GLP-1 and
gastrin increased pancreatic -cell mass twofold over the
pretreatment level (0.57 	 0.24 vs. 0.25 	 0.10 mg; P 
0.15, NS), and 100 g/kg GLP-1 plus gastrin treatment
increased pancreatic -cell mass threefold over the pre-
treatment level (0.74 	 0.25 vs. 0.25 	 0.10 mg; P 
 0.05).
Pancreatic -cell mass in acutely diabetic mice before
treatment (0.25 	 0.10 mg) was 18% of normal (1.40 	 0.22
mg), whereas 100 g/kg GLP-1 plus gastrin increased
pancreatic -cell mass to 53% of normal (0.74 	 0.25 vs.
1.40 	 0.22 mg).
Correlations of blood glucose with pancreatic insulin
and -cell mass. Reductions in hyperglycemia by gastrin,
GLP-1, and GLP-1 plus gastrin correlated signiﬁcantly with
increases in pancreatic insulin content (Fig. 3A) and -cell
mass (Fig. 3B). Restoration of the pancreatic insulin
content to 30% of normal (3 vs. 10 g in NOD-scid
mice) was sufﬁcient to bring the blood glucose level down
to normal (5.4 	 0.6 mmol/l in NOD-scid mice) (Fig. 3A).
Similarly, restoration of the pancreatic -cell mass to
35% of normal (0.5 vs. 1.4 mg in NOD-scid mice) was
sufﬁcient to correct hyperglycemia (Fig. 3B).
Pancreatic histology. Histological examination of NOD
mice pancreata after diabetes onset revealed islets heavily
inﬁltrated by leukocytes and few islets with remaining
-cells (Fig. 4A). Vehicle-treated mice were severely hy-
perglycemic, and their islets were heavily inﬁltrated by
leukocytes and almost devoid of -cells (Fig. 4B). In
contrast, normoglycemia was restored in GLP-1– and
gastrin-treated mice, and islets with abundant insulin-
containing -cells were found; also, some islets were
surrounded by leukocytes, but most were not inﬁltrated
(Fig. 4C).
Pancreatic -cell replication, apoptosis, and neogenesis.
The increase in pancreatic -cells in GLP-1– and gastrin-
treated NOD mice (Fig. 5A) was associated with a signif-
icant decrease in -cell apoptosis (Fig. 5B). Pancreatic
-cell replication rates were low (1% of total -cells) and
not changed by GLP-1 and gastrin therapy (Fig. 5C). In
contrast, replication of pancreatic duct cells was signiﬁ-
cantly increased by GLP-1 and gastrin (Fig. 5D). Also,
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FIG. 3. Partial restoration of the pancreatic insulin content (A) and
-cell mass (B) corrects hyperglycemia in NOD mice. The mice were
treated for 3 weeks with vehicle (E, n  4), 1.5 g/kg gastrin (Œ, n  4),
10 or 100 g/kg GLP-1 (F, n  14), and 1.5 g gastrin plus 10 or 100
g/kg GLP-1 (, n  12). Blood glucose values at 5 weeks after
treatments were stopped (or earlier if blood glucose was >27.5 mmol/l;
Fig. 1) are plotted against the corresponding values for pancreatic
insulin content (A) and -cell mass (B) in each mouse. The curved lines
were derived using nonlinear regression analysis (r  0.985; P < 0.001
in A, and r  0.874; P < 0.001 in B). Shaded bars show the mean  SD
range for normal values, as determined in NOD-scid mice (n  6).
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FIG. 4. Photomicrographs of pancreatic tissue sections. A:A nN O D
mouse pancreas 5 days after diabetes onset and before the start of
treatments. Islets are inﬁltrated by leukocytes (dark blue-stained),
and the few islets with remaining -cells (brown-stained with insulin
antibody) are surrounded and inﬁltrated by abundant leukocytes
(inset a). B: An NOD mouse pancreas after treatment with vehicle
for 3 weeks and an additional 3 weeks without treatment. Islets are
heavily inﬁltrated by leukocytes and almost devoid of -cells (inset
b). C: An NOD mouse pancreas after treatment with 100 g/kg GLP-1
and 1.5 g/kg gastrin for 3 weeks and an additional 5 weeks without
treatment. Islets with abundant insulin-stained -cells are found,
and some islets are surrounded by leukocytes, but most are not
inﬁltrated and destroyed (inset c). (Please see http://dx.doi.org/
10.2337/db08-0688 for a high-quality digital representation of this
ﬁgure.)
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after GLP-1 and gastrin treatment (6 	 1% of duct cells)
than before treatment (2 	 1%) or after vehicle treatment
(1 	 1%) (Fig. 5E and F).
Insulin autoantibodies. Insulin autoantibodies were
present in acutely diabetic NOD mice before treatment,
and these antibodies rose to very high levels in vehicle-
treated mice, whereas insulin autoantibodies were unde-
tectable in GLP-1– and gastrin-treated mice (Fig. 6). This
suggested that GLP-1 and gastrin therapy had altered the
autoimmune response against -cells.
Adoptive transfer of diabetes. Splenocytes from GLP-1–
and gastrin-treated diabetic NOD mice in remission pro-
tected against diabetes development when mixed with
diabetogenic splenocytes and transferred into immunode-
ﬁcient NOD-scid mice (Fig. 7). This suggested activation of
immunoregulatory cells in NOD mice treated with GLP-1
and gastrin.
Islet transplantation. Islet grafts were destroyed, and
diabetes recurred within 14 days after transplantation in
all mice treated with vehicle, whereas 88% (seven of eight)
of islet grafts survived and maintained normoglycemia in
GLP-1– and gastrin-treated mice (Fig. 8A). Histological
examination of the islet grafts showed abundant insulin-
stained cells interspersed with leukocytes in islet grafts of
GLP-1– and gastrin-treated mice (Fig. 8B), whereas no
insulin-stained cells remained in islet grafts of vehicle-
treated mice (Fig. 8C). Recovery of -cells in islet grafts of
GLP-1– and gastrin-treated mice was associated with
signiﬁcantly reduced apoptosis of -cells (Fig. 9D) and not
with any change in replication of -cells (Fig. 9C), similar
to the ﬁndings in the pancreas (Fig. 5B and C).
Cytokines expressed in islet grafts. Fewer leukocytes
produced IFN- in GLP-1– and gastrin-treated mice (Fig.
10B) than in vehicle-treated mice (Fig. 10A), and the
difference was signiﬁcant (Fig. 10C). In contrast, more
leukocytes produced TGF-1 in GLP-1– and gastrin-
treated mice (Fig. 10E) than in vehicle-treated mice (Fig.
10D), and the difference was signiﬁcant (Fig. 10F). There-
fore, GLP-1 and gastrin appeared to have shifted the
immune response from a cytotoxic (IFN-) to a regulatory
(TGF-1) one.
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Previous reports of diabetes reversal in NOD mice after
immunotherapy suggested -cell regeneration (28–31).
More recent studies, however, revealed that immunother-
apy abrogated autoimmunity and allowed existent -cells
to recover their insulin secretory function, but -cell mass
did not increase (32,33). Also, addition of the GLP-1
analog, exendin-4, to anti-CD3 immunotherapy improved
-cell function but did not increase -cell mass in diabetic
NOD mice (34). Similarly, in the present study, we found
that GLP-1 therapy alone did not signiﬁcantly increase
either insulin content or -cell mass in diabetic NOD mice;
however, addition of gastrin to GLP-1 signiﬁcantly in-
creased both insulin content and -cell mass in the dia-
betic mice. Gastrin induces -cell neogenesis from
pancreatic exocrine duct cells (19,20) and potentiates the
growth-promoting effects of EGF on the pancreatic -cell
mass (21,22). We previously reported that this action of
gastrin is via induction of the pancreatic and duodenal
homeobox transcription factor, PDX-1, in pancreatic duct
cells followed by insulin expression in these cells (35).
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FIG. 7. GLP-1 and gastrin combination therapy induces immunoregu-
latory cell activity in NOD mice. The median time (50% diabetes
incidence) for diabetes onset (blood glucose >12 mmol/l) in NOD-
scid mice was 18 days when the mice were injected intravenously
with 1.5  10
7 splenic cells from diabetic NOD mice (‚, n  5) and
39 days when injected with 0.5  10
7 splenic cells from diabetic NOD
mice (E, n  8). Diabetes onset was delayed to a median of 69 days
when NOD-scid mice were injected with 0.5  10
7 splenic cells from
diabetic NOD mice mixed with 1.0  10
7 splenic cells from GLP-1–
plus gastrin-treated NOD mice (F, n  8) and to 107 days when
NOD-scid mice were injected with 0.5  10
7 splenic cells from
diabetic NOD mice mixed with 3.0  10
7 splenic cells from GLP-1–
plus gastrin-treated NOD mice (f, n  8).
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sentation of this ﬁgure.)
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ulate epithelial cells in the pancreatic ducts to differentiate
along a -cell pathway.
GLP-1 and exendin-4 can increase the -cell mass in
rodents with experimentally induced deﬁcits in -cell
mass through stimulation of -cell proliferation and neo-
genesis and inhibition of -cell apoptosis (12–15). GLP-1
(16) and exendin-4 (17) reduced insulitis and protected
-cells in NOD mice when given before diabetes onset, and
-cell neogenesis from duct cells was reported (16). In the
present study, we found that the increase in pancreatic
-cell mass induced by GLP-1 and gastrin combination
therapy was associated with an increase in duct-associ-
ated -cells and a decrease in -cell apoptosis. We do not
know, however, to what extent the increase in duct-
associated -cells induced by GLP-1 and gastrin may
have contributed to the increase in -cell mass. We
evaluated -cell replication, neogenesis, and apoptosis
at only one time point, 3–5 weeks after vehicle or GLP-1
and gastrin treatments, and compared these values to
the pretreatment (baseline) values. Therefore, we can-
not exclude an earlier contribution of -cell prolifera-
tion during the GLP-1– and gastrin-induced restoration
of -cell mass and normoglycemia. Also, a time course
study of PDX-1 and insulin staining of ductal cells would
be required to provide more deﬁnitive evidence for
-cell neogenesis by GLP-1 and gastrin. Regarding the
antiapoptotic effect of GLP-1 and gastrin on -cells, this
may have been conferred on preexistent and on newly
generated -cells.
Interestingly, partial (35%) restoration of the pancre-
atic -cell mass by GLP-1 and gastrin was sufﬁcient to
restore normoglycemia in the diabetic NOD mice. This is
similar to ﬁndings in obese human subjects in whom
hyperglycemia and type 2 diabetes was observed only after
pancreatic -cell mass was reduced below approximately
one-third of that in normoglycemic individuals (36). The
ﬁnding that normoglycemia persisted for at least 5 weeks
after the 3-week course of GLP-1 and gastrin suggested
that in addition to restoration of -cell mass, the expected
autoimmune response had been arrested. We found that
insulin autoantibodies rose to extremely high levels as
diabetes progressed in vehicle-treated mice, whereas
these autoantibodies were undetectable in a few mice
treated with either GLP-1 or gastrin and in all the mice
treated with GLP-1 and gastrin. This suggests that both
GLP-1 and gastrin contributed to regulating the autoim-
mune response against islet -cells. An adoptive transfer
study suggested activation of immunoregulatory cell activ-
ity by GLP-1 and gastrin. In addition, the expected auto-
immune response to syngeneic islet transplantation was
largely abolished by GLP-1 and gastrin. Although leuko-
cytic inﬁltration of the islet graft was extensive in GLP-1–
and gastrin-treated mice, -cells were not destroyed. Im-
portantly, survival of -cells in islet grafts of GLP-1– and
gastrin-treated mice could be attributed to the antiapop-
totic effects of GLP-1 and gastrin on -cells and not to any
stimulatory effects on -cell replication, similar to our
ﬁndings in the pancreas of GLP-1– and gastrin-treated
mice.
Together with the antiapoptotic effect of GLP-1 and
gastrin on -cells in the islet graft, there was a shift in the
cytokine proﬁle of the islet graft–inﬁltrating leukocytes
from IFN- to TGF-1 production. IFN-–producing leu-
kocytes in islets are associated with -cell destruction
(37), whereas TGF-1–producing leukocytes regulate
(suppress) the autoimmune response (38). Therefore, the
GLP-1– and gastrin-induced shift from an IFN- to a
TGF-1 type response may explain why the leukocytic
inﬁltrate did not damage -cells in the graft. Alternatively,
or in addition, GLP-1 and gastrin may have had direct
antiapoptotic effects on -cells, as reported for GLP-1 (15).
Further studies are required to determine how GLP-1 and
gastrin shifted the immune response from a cytotoxic to a
regulatory one and to determine whether this was second-
ary to the antiapoptotic effects of GLP-1 and gastrin on
-cells and/or a direct action of the gastrointestinal pep-
tides on cells of the immune system. GLP-1 receptor
mRNA transcripts have been detected in spleen, thymus,
and lymph nodes of NOD mice (17). Also, a preliminary
report demonstrated the expression of the GLP-1 receptor
on human T-cells and exogenous GLP-1–modulated CD8

T-cell migration in vitro (39). Further studies of the
responses of leukocytes from GLP-1– and gastrin-treated
NOD mice to NOD islet antigens in vitro may help to
clarify the mechanisms for the immunological effects that
we observed in vivo.
In summary, a short course of GLP-1 and gastrin par-
tially restored pancreatic -cell mass and arrested autoim-
mune destruction of -cells in acutely diabetic NOD mice,
thereby restoring normoglycemia. These ﬁndings suggest
that GLP-1 and gastrin combination therapy may target
both the cellular mechanisms that promote growth and
survival of -cells and the immunological mechanisms that
destroy -cells, thereby offering a promising strategy for
correction of the -cell loss in type 1 diabetes.
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